论文部分内容阅读
目的分析原发性肺癌患者血清内皮抑素含量与肿瘤临床病理特征及预后的关系。方法 ELISA法检测57例原发性肺癌(A组)及27例肺良性病变(B组)患者术前血清内皮抑素含量。结果 A组血清内皮抑素含量为(132.73±31.69)μg/L,显著高于B组的(84.56±15.47)μg/L(P<0.01)。淋巴结及远处转移组内皮抑素含量明显高于未转移组(P<0.05);肺腺癌患者血清内皮抑素水平高于鳞癌、小细胞癌患者;Ⅲ～Ⅳ期患者血清内皮抑素水平高于Ⅰ～Ⅱ期(P<0.01)。结论肺癌患者血清内皮抑素含量显著增高,且与肿瘤组织学类型、分化程度、TNM分期、淋巴结转移相关,是预测肿瘤恶性行为和评估预后的有效指标。
Objective To analyze the relationship between the serum level of endostatin and the clinicopathological features and prognosis of patients with primary lung cancer. Methods The serum levels of endostatin in 57 patients with primary lung cancer (group A) and 27 patients with benign lung disease (group B) were detected by ELISA. Results The serum level of endostatin in group A was (132.73 ± 31.69) μg / L, which was significantly higher than that in group B (84.56 ± 15.47) μg / L (P <0.01). The levels of endostatin in lymph node and distant metastasis group were significantly higher than those in non-metastasis group (P <0.05). The serum endostatin level in patients with lung adenocarcinoma was higher than that in squamous cell carcinoma and small cell carcinoma. The serum levels of endostatin The level was higher than Ⅰ ~ Ⅱ (P <0.01). Conclusions Serum endostatin levels in patients with lung cancer are significantly increased, and are correlated with histological types, differentiation degree, TNM stage and lymph node metastasis. It is an effective index for predicting malignant behavior of tumor and assessing prognosis.